Humacyte Statistics

Total Valuation

Humacyte has a market cap or net worth of $260.60 million. The enterprise value is $296.95 million.

Market Cap	260.60M
Enterprise Value	296.95M

Important Dates

The next estimated earnings date is Friday, May 9, 2025, before market open.

Earnings Date	May 9, 2025
Ex-Dividend Date	n/a

Share Statistics

Humacyte has 155.12 million shares outstanding. The number of shares has increased by 14.56% in one year.

Current Share Class	155.12M
Shares Outstanding	155.12M
Shares Change (YoY)	+14.56%
Shares Change (QoQ)	+6.34%
Owned by Insiders (%)	7.73%
Owned by Institutions (%)	27.38%
Float	121.94M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	35.66
PB Ratio	-4.95
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 2.40

Current Ratio	2.40
Quick Ratio	2.25
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-12.33

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	-53.74%
Return on Invested Capital (ROIC)	-142.68%
Return on Capital Employed (ROCE)	-97.01%
Revenue Per Employee	n/a
Profits Per Employee	-$675,914
Employee Count	220
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -45.75% in the last 52 weeks. The beta is 1.62, so Humacyte's price volatility has been higher than the market average.

Beta (5Y)	1.62
52-Week Price Change	-45.75%
50-Day Moving Average	2.78
200-Day Moving Average	4.89
Relative Strength Index (RSI)	38.93
Average Volume (20 Days)	6,588,486

Short Selling Information

The latest short interest is 27.14 million, so 17.49% of the outstanding shares have been sold short.

Short Interest	27.14M
Short Previous Month	26.60M
Short % of Shares Out	17.49%
Short % of Float	22.25%
Short Ratio (days to cover)	6.32

Income Statement

Revenue	n/a
Gross Profit	-88.60M
Operating Income	-114.40M
Pretax Income	-105.70M
Net Income	-148.70M
EBITDA	-107.21M
EBIT	-114.40M
Earnings Per Share (EPS)	-$1.26

Full Income Statement

Balance Sheet

The company has $44.94 million in cash and $81.29 million in debt, giving a net cash position of -$36.35 million or -$0.23 per share.

Cash & Cash Equivalents	44.94M
Total Debt	81.29M
Net Cash	-36.35M
Net Cash Per Share	-$0.23
Equity (Book Value)	-52.67M
Book Value Per Share	-0.41
Working Capital	27.91M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$98.12 million and capital expenditures -$1.57 million, giving a free cash flow of -$99.69 million.

Operating Cash Flow	-98.12M
Capital Expenditures	-1.57M
Free Cash Flow	-99.69M
FCF Per Share	-$0.64

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Humacyte does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-14.56%
Shareholder Yield	n/a
Earnings Yield	-57.06%
FCF Yield	-38.26%

Analyst Forecast

The average price target for Humacyte is $14.60, which is 779.52% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$14.60
Price Target Difference	779.52%
Analyst Consensus	Strong Buy
Analyst Count	6
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	1